Abstract
Osteoporotic fractures, particularly hip fractures, can have a devastating impact on the well-being of the elderly population. Recently, two population-based observational studies reported a highly important association between the use of potent acid suppressive therapy and an increased risk of hip fractures. The mechanisms underlying such an association are not clear. However, a careful review of the existing evidence seems to suggest that the main physiologic consequences of proton pump inhibitor therapy may each have a theoretical influence on bone metabolism. Specifically, inhibition of the osteoclastic proton pumps may reduce bone resorption, while profound acid suppression could potentially hamper intestinal calcium absorption, and secondary hypergastrinemia may enhance bone resorption through the induction of parathyroid gland hyperplasia. However, the existing data are clearly too limited for us to draw any definitive conclusions, and more studies are urgently needed to delineate the physiologic relevance of these theoretical mechanistic links, individually and collectively.
Keywords: Osteoporosis, Proton Pump Inhibitor, metabolism, hypergastrinemia, parathyroid gland
Current Drug Safety
Title: Proton Pump Inhibitor Therapy and Osteoporosis
Volume: 3 Issue: 3
Author(s): Yu-Xiao Yang
Affiliation:
Keywords: Osteoporosis, Proton Pump Inhibitor, metabolism, hypergastrinemia, parathyroid gland
Abstract: Osteoporotic fractures, particularly hip fractures, can have a devastating impact on the well-being of the elderly population. Recently, two population-based observational studies reported a highly important association between the use of potent acid suppressive therapy and an increased risk of hip fractures. The mechanisms underlying such an association are not clear. However, a careful review of the existing evidence seems to suggest that the main physiologic consequences of proton pump inhibitor therapy may each have a theoretical influence on bone metabolism. Specifically, inhibition of the osteoclastic proton pumps may reduce bone resorption, while profound acid suppression could potentially hamper intestinal calcium absorption, and secondary hypergastrinemia may enhance bone resorption through the induction of parathyroid gland hyperplasia. However, the existing data are clearly too limited for us to draw any definitive conclusions, and more studies are urgently needed to delineate the physiologic relevance of these theoretical mechanistic links, individually and collectively.
Export Options
About this article
Cite this article as:
Yang Yu-Xiao, Proton Pump Inhibitor Therapy and Osteoporosis, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699414
DOI https://dx.doi.org/10.2174/157488608785699414 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Development of Immunopharmacotherapy Against Drugs of Abuse
Current Drug Discovery Technologies Planar Chip Sensors for Assessment of Nicotine
Current Analytical Chemistry Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews From Gastroprotective to Ulcerogenic Effects of Glucocorticoids: Role of Long-Term Glucocorticoid Action
Current Pharmaceutical Design Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Immunosuppression in Liver Transplantation
Current Drug Targets Preventive Strategies for Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Current Pharmaceutical Design How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Current Pharmaceutical Design The Realization of the Brain-Gut Interactions with Corticotropin-Releasing Factor and Glucocorticoids
Current Neuropharmacology Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine
Anti-Cancer Agents in Medicinal Chemistry Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry